September 2024 - Milwaukee Institute for Drug Discovery

Milwaukee Team Wins NIH R01 to Develop Novel Anxiolytic Compounds Targeting the Endocannabinoid System

Nearly 1/3 of Americans will experience an anxiety disorder in their lifetime resulting in impaired social function and reduction of quality of life. Unfortunately, existing anxiety medications suffer from delayed or inadequate efficacy and sedative-hypnotic effects. Development of additional anxiolytics… Read More

Professor Shama Mirza received the Advancing a Healthier Wisconsin Endowment grant in collaboration with Dr. Mona Al-Gizawiy, an assistant professor of biophysics at the Medical College of Wisconsin.

Glioblastoma (GBM) is an extremely aggressive cancer for which there are limited treatment options. Despite recent advances in therapy, the prognosis remains dismal and patient survival is short. After standard therapy, the recurrent tumors become resistant to therapy and render… Read More